SCHEMBL18328129

SCHEMBL18328129

CC1CC2(CCNCC2)CN1C(=O)OC(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
ACACB O00763 4/20 0.39
NR1H2 P55055 1/20 0.33
CYP1A2 P05177 1/20 0.33
EPHX2 P34913 1/20 0.32
CHRM2 P08172 1/20 0.32
CHRM1 P11229 1/20 0.32
CHRM3 P20309 1/20 0.32
KDM1A O60341 1/20 0.31
DDB1 Q16531 1/20 0.31
CRBN Q96SW2 1/20 0.31
HSD17B10 Q99714 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL38656021 0.92 ACACB (0.38) ACACBEPHX2CHRM2CHRM1CHRM3
SCHEMBL16800261 0.90 ACACB (0.40) ACACBNR1H2EPHX2CHRM2CHRM1
SCHEMBL19792176 0.90 ACACB (0.40) ACACBNR1H2EPHX2CHRM2CHRM1
SCHEMBL30172620 0.87 ACACB (0.42) ACACBNR1H2CYP1A2EPHX2KDM1A
SCHEMBL25730009 0.87 ACACB (0.39) ACACBEPHX2CHRM2CHRM1CHRM3
SCHEMBL25922603 0.85 ACACB (0.38) ACACBEPHX2CHRM2CHRM1CHRM3
SCHEMBL27225632 0.83 NR1H2 (0.37) ACACBNR1H2CYP1A2EPHX2CHRM2
SCHEMBL30749399 0.81 PEPD (0.42) NR1H2CYP1A2EPHX2HSD17B10
SCHEMBL20553992 0.81 CHRM2 (0.41) ACACBNR1H2CYP1A2EPHX2CHRM2
SCHEMBL20553993 0.81 CHRM2 (0.41) ACACBNR1H2CYP1A2EPHX2CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021055756-A1 SPIROCYCLIC ANDROGEN RECEPTOR PROTEIN DEGRADERS THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2021-03-25 WO disclosed
WO-2016203405-A1 COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 NOVARTIS AG (CH) 2016-12-22 WO disclosed
WO-2016203406-A1 COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 NOVARTIS AG (CH) 2016-12-22 WO disclosed